417 related articles for article (PubMed ID: 8819509)
21. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
Ohmori K; Hayashi K; Kaise T; Ohshima E; Kobayashi S; Yamazaki T; Mukouyama A
Jpn J Pharmacol; 2002 Apr; 88(4):379-97. PubMed ID: 12046981
[TBL] [Abstract][Full Text] [Related]
22. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
Greiner JV; Udell IJ
Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
24. Antiallergic anti-inflammatory effects of H1-antihistamines in humans.
Assanasen P; Naclerio RM
Clin Allergy Immunol; 2002; 17():101-39. PubMed ID: 12113215
[TBL] [Abstract][Full Text] [Related]
25. In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent.
Benavides J; Schoemaker H; Dana C; Claustre Y; Delahaye M; Prouteau M; Manoury P; Allen J; Scatton B; Langer SZ
Arzneimittelforschung; 1995 May; 45(5):551-8. PubMed ID: 7612054
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the conjunctival toxicity of topical ocular antiallergic agents.
Lee JS; Lee JE; Kim N; Oum BS
J Ocul Pharmacol Ther; 2008 Dec; 24(6):557-62. PubMed ID: 19049267
[TBL] [Abstract][Full Text] [Related]
27. In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen.
Schoch C
J Ocul Pharmacol Ther; 2003 Feb; 19(1):75-81. PubMed ID: 12648306
[TBL] [Abstract][Full Text] [Related]
28. Effects of antihistamines on inflammatory mediators.
Naclerio RM
Ann Allergy; 1993 Sep; 71(3):292-5. PubMed ID: 7690526
[TBL] [Abstract][Full Text] [Related]
29. Effect of (Z)-11-[3-(dimethylamino) propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride on experimental allergic conjunctivitis and rhinitis in rats and guinea pigs.
Kamei C; Sugimoto Y; Nakamura S; Zhong C
Arzneimittelforschung; 1995 Sep; 45(9):1005-8. PubMed ID: 7488300
[TBL] [Abstract][Full Text] [Related]
30. Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein.
Kishimoto K; Kaneko S; Ohmori K; Tamura T; Hasegawa K
Mediators Inflamm; 2006; 2006(1):42726. PubMed ID: 16864903
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
Abelson MB; Spangler DL; Epstein AB; Mah FS; Crampton HJ
Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
[TBL] [Abstract][Full Text] [Related]
32. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
Berdy GJ; Spangler DL; Bensch G; Berdy SS; Brusatti RC
Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
[TBL] [Abstract][Full Text] [Related]
34. Effects of E-4716, a new antihistaminic with antiallergic properties, on chemical mediators induction of immunologic reactions.
Gutiérrez B; Dordal A; Fort M; Galicia J; Farré AJ
Methods Find Exp Clin Pharmacol; 1996; 18(6):397-406. PubMed ID: 8892269
[TBL] [Abstract][Full Text] [Related]
35. Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat.
Schoch C
Ocul Immunol Inflamm; 2005 Feb; 13(1):39-44. PubMed ID: 15804768
[TBL] [Abstract][Full Text] [Related]
36. Inhibitors of tryptase as mast cell-stabilizing agents in the human airways: effects of tryptase and other agonists of proteinase-activated receptor 2 on histamine release.
He S; Aslam A; Gaça MD; He Y; Buckley MG; Hollenberg MD; Walls AF
J Pharmacol Exp Ther; 2004 Apr; 309(1):119-26. PubMed ID: 14722328
[TBL] [Abstract][Full Text] [Related]
37. A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase.
He S; Gaça MD; Walls AF
J Pharmacol Exp Ther; 1998 Jul; 286(1):289-97. PubMed ID: 9655871
[TBL] [Abstract][Full Text] [Related]
38. Human conjunctival epithelial cells express histamine-1 receptors coupled to phosphoinositide turnover and intracellular calcium mobilization: role in ocular allergic and inflammatory diseases.
Sharif NA; Xu SX; Magnino PE; Pang IH
Exp Eye Res; 1996 Aug; 63(2):169-78. PubMed ID: 8983974
[TBL] [Abstract][Full Text] [Related]
39. Human basophil/mast cell releasability. IX. Heterogeneity of the effects of opioids on mediator release.
Stellato C; Cirillo R; de Paulis A; Casolaro V; Patella V; Mastronardi P; Mazzarella B; Marone G
Anesthesiology; 1992 Nov; 77(5):932-40. PubMed ID: 1280014
[TBL] [Abstract][Full Text] [Related]
40. Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability.
Beauregard C; Stephens D; Roberts L; Gamache D; Yanni J
J Ocul Pharmacol Ther; 2007 Aug; 23(4):315-20. PubMed ID: 17803429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
